Pamela A. Haile - Concepedia

Author

Pamela A. Haile

Also Known As

BindingDB, Crimmins, Michael T., Haile, P.A., Haile, Pamela A., McDougall, Patrick J., P.A. Haile, Pamela A. Haile, Pamela Haile, Pamela A. Haile, Pamela A. Haile

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)South College GlaxoSmithKline (United Kingdom)University of North Carolina at Chapel Hill University of California, Irvine

About

Pamela A. Haile is an author at GlaxoSmithKline (United States) specializing in medicine, drug discovery, and organic chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	743
2	Natural Sciences	4	4	176
3	Engineering	3	3	120
4	Biochemistry	3	3	113
5	Biomolecular Engineering	2	2	102

Pamela A. Haile

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity Pratyusha Mandal, Scott B. Berger, Sirika Pillay, Molecular Cell Cell RegulationPronecrotic Kinase ActivityReceptor Tyrosine KinaseApoptosisAutophagy	2014	593
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2 Alina Mares, Afjal H. Miah, Ian E. Smith, Communications Biology	2020	209
The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis, Journal of Medicinal Chemistry	2016	122
Optimization of a Series of RIPK2 PROTACs Afjal H. Miah, Ian E. Smith, M.D. Rackham, Journal of Medicinal Chemistry	2021	65
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases Pamela A. Haile, Linda Casillas, Bartholomew J. Votta, Journal of Medicinal Chemistry Chronic Inflammatory DiseasesDrug TargetImmunologyCell DeathPathology	2019	65
Identification of Benzimidazole Diamides as Selective Inhibitors of the Nucleotide-Binding Oligomerization Domain 2 (NOD2) Signaling Pathway David J. Rickard, Clark A. Sehon, Viera Kasparcova, PLoS ONE Drug TargetInnate Immune SystemImmunologyMolecular BiologyCell Death	2013	55
Enantioselective Total Synthesis of Brevetoxin A: Unified Strategy for the B, E, G, and J Subunits Michael T. Crimmins, J. Michael Ellis, Kyle A. Emmitte, Chemistry - A European Journal Combinatorial ChemistryBioorganic ChemistryEngineeringMolecular BiologyOrganic Chemistry	2009	53
Total Synthesis of Brevetoxin A Michael T. Crimmins, J. Lucas Zuccarello, J. Michael Ellis, Organic Letters Cross-coupling ReactionBiosynthesisBioorganic ChemistryEngineeringBiochemistry	2008	49
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel Pamela A. Haile, Linda Casillas, Michael J. Bury, ACS Medicinal Chemistry Letters	2018	35
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors Curt D. Haffner, Adam K. Charnley, Christopher Aquino, ACS Medicinal Chemistry Letters	2019	26

Page 1